KRAS G12C

Clinical trials for KRAS G12C explained in plain language.

Never miss a new study

Get alerted when new KRAS G12C trials appear

Sign up with your email to follow new studies for KRAS G12C, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Our safety recommendation!

By submitting, you agree to our Terms of use

Trials to join now! 6 Not yet recruiting 1 Not yet finished but already full! 3 Completed 1

New pill targets Hard-to-Treat cancers in 334-Patient trial

Disease control Completed

This study tested a drug called GFH925 in 334 people with advanced solid tumors that have a specific genetic change called KRAS G12C. The goal was to check the drug's safety, find the right dose, and see if it shrinks tumors in cancers like lung and colorectal cancer. Participant…

Matched conditions: KRAS G12C

Phase: PHASE1, PHASE2 • Sponsor: Innovent Biologics (Suzhou) Co. Ltd. • Aim: Disease control

Last updated May 14, 2026 12:01 UTC

KRAS G12C

Get alerted when new KRAS G12C trials appear

New pill targets Hard-to-Treat cancers in 334-Patient trial